Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-26T00:26:03.141Z Has data issue: false hasContentIssue false

Sepsis update: management of severe sepsis and septic shock in the emergency department after the withdrawal of Xigris

Published online by Cambridge University Press:  11 May 2015

Robert S. Green*
Affiliation:
Department of Emergency Medicine and Division of Critical Care Medicine, Department of Anesthesia, Queen Elizabeth II Health Science Centre, Capital Health, and Department of Emergency Medicine, Dalhousie University, Halifax, NS
Dennis Djogovic
Affiliation:
University of Alberta, Edmonton, AB
Daniel Howes
Affiliation:
Division of Critical Care, Department of Emergency Medicine, Queen's University, and Kingston Resuscitation Institute, Kingston, ON
*
Department of Emergency Medicine, Division of Critical Care Medicine, Department of Anesthesia, Room 377 Bethune Building, 1276 South Park Street, Halifax, NS B3H 2Y9; [email protected].

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial/Commentary
Copyright
Copyright © Canadian Association of Emergency Physicians 2012

References

REFERENCES

1.Green, RS, Djogovic, D, Gray, S, et al. CAEP Critical Care Interest Group. Canadian Association of Emergency Physicians sepsis guidelines: the optimal management of severe sepsis in Canadian emergency departments. CJEM 2008;10:443–59.CrossRefGoogle ScholarPubMed
2.Russell, JA. Management of sepsis. N Engl J Med 2006;355:1699–713, doi:10.1056/NEJMra043632.CrossRefGoogle ScholarPubMed
3.Zanotti, S, Kumar, A, Kumar, A. Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs 2002;11:1061–75, doi:10.1517/13543784.11.8.1061.Google Scholar
4.Bernard, GR, Vincent, JL, Laterre, PF, et al. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699709, doi:10.1056/NEJM200103083441001.Google Scholar
5.Warren, HS, Suffredini, AF, Eichacker, PQ, et al. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002;347:1027–30, doi:10.1056/NEJMsb020574.Google Scholar
6.Siegel, JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002;347:1030–4, doi:10.1056/NEJMsb021512.CrossRefGoogle ScholarPubMed
7.Dellinger, RP, Carlet, JM, Masur, H, et al. Surviving sepsis campaign guidelines formanagement of severe sepsis and septic shock. Crit Care Med 2004;32:858–73, doi:10.1097/01.CCM.0000117317.18092.E4.Google Scholar
8.Eichacker, PQ, Natanson, C, Danner, RL. Surviving sepsis—practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006;355:1640–2, doi:10.1056/NEJMp068197.CrossRefGoogle ScholarPubMed
9.Abraham, E, Laterre, PF, Garg, R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332–41, doi:10.1056/NEJMoa050935.Google Scholar
10.Nadel, S, Goldstein, B, Williams, MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369:836–43, doi:10.1016/S0140-6736(07)60411-5.Google Scholar
11.Finfer, S, Ranieri, VM, Thompson, BT, et al. Design, conduct, analysis and reporting of a multinational placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008;34:1935–47, doi:10.1007/s00134-008-1266-6.CrossRefGoogle ScholarPubMed
12.Krauskopf, L, Pierson, R. UPDATE 4-Lilly pulls sepsis drug Xigris, no benefit found. Reuters.com US Edition.October 25, 2011. Available at: http://www.reuters.com/article/2011/10/25/elililly-idUSN1E79O08320111025 (accessed Dec 8, 2011).Google Scholar
13.Ferrer, R, Artigas, A, Levy, MM, et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008;299:2294–303, doi:10.1001/jama.299.19.2294.CrossRefGoogle ScholarPubMed
14.Puskarich, MA, Marchick, MR, Kline, JA, et al. One year mortality of patients treated with an emergency department based early goal directed therapy protocol for severe sepsis and septic shock: a before and after study. Crit Care 2009;13:R167. [Epub 2009 Oct21], doi:10.1186/cc8138.CrossRefGoogle ScholarPubMed